Dietary advanced glycation end-product restriction for the attenuation of insulin resistance, oxidative stress and endothelial dysfunction: A systematic review

European Journal of Clinical Nutrition

Volumn 67, Issue 3, 2013, Pages 239-248

  Kellow, N J ^a   Savige, G S ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

advanced glycation end product; diabetes; dietary AGE restriction; humans; inflammation; systematic review

Indexed keywords

6 N CARBOXYMETHYLLYSINE; 8 ISOPROSTANE; ADVANCED GLYCATION END PRODUCT; LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; AMINO ACID BLOOD LEVEL; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIET RESTRICTION; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT;

DIABETES MELLITUS; DIET; ENDOTHELIUM; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN RESISTANCE; LYSINE; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY;

EID: 84875210316     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2012.220     Document Type: Review

References (60)

1. Barlovic DP, Thomas MC, Jandeleit-Dahm K. Cardiovascular disease: what's all the AGE/RAGE about? Cardiovasc Hematol Disord Drug Targets 2010; 10: 7-15.
2. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007; 13: 2832-2836.
3. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-886.
4. Tahara N, Yamagishi S, Matsui T, Takeuchi M, Nitta Y, Kodama N et al. Serum levels of advanced glycation endproducts (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 2012; 30: 42-48.
5. Tessier FJ, Birlouez-Aragon I. Health effects of dietary Maillard reaction products: the results of ICARE and other studies. Amino Acids 2012; 42: 1119-1131.
6. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci 2005; 1043: 461-466.
7. Faist V, Erbersdobler HF. Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann Nutr Metab 2001; 45: 1-12.
8. Delgado-Andrade C, Tessier FJ, Niquet-Leridon C, Seiquer I, Pilar Navarro M. Study of the urinary and faecal excretion of N (epsilon)-carboxymethyllysine in young human volunteers. Amino Acids 2012; 43: 595-602.
9. Kankova K, Sebekova K. Genetic variability in the RAGE gene: possible implications for nutrigenetics, nutrigenomics, and understanding the susceptibility to diabetic complications. Mol Nutr Food Res 2005; 49: 700-709.
10. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 2007; 62: 427-433.
11. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, Baliga S et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 2003; 42: 532-538.
12. Chao PC, Huang CN, Hsu CC, Yin MC, Guo YR. Association of dietary AGEs with circulating AGEs, glycated LDL, IL-1alpha and MCP-1 levels in type 2 diabetic patients. Eur J Nutr 2010; 49: 429-434.
13. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 2011; 1243: 88-102.
14. Coughlan MT, Yap FY, Tong DC, Andrikopoulos S, Gasser A, Thallas-Bonke V et al. Advanced glycation end products are direct modulators of beta-cell function. Diabetes 2011; 60: 2523-2532.
15. Fiory F, Lombardi A, Miele C, Giudicelli J, Beguinot F, Van Obberghen E. Methyl-glyoxal impairs insulin signalling and insulin action on glucose-induced insulin secretion in the pancreatic beta cell line INS-1E. Diabetologia 2011; 54: 2941-2952.
16. Vlassara H, Striker GE. AGE restriction in diabetes mellitus: a paradigm shift. Nat Rev Endocrinol 2011; 7: 526-539.
17. Koschinsky T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997; 94: 6474-6479.
18. Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonu-trition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001; 286: 944-953.
19. Hedges I, Olkin I. Statistical Methods for Meta-analysis. 1st edn. Academic Press: Orlando, FL, USA, 1985.
20. White IR, Thomas J. Standardized mean differences in individually- randomized and cluster-randomized trials, with applications to meta-analysis. Clin Trials 2005; 2: 141-151.
21. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) Higgins JPT GS (ed.) The Cochrane Collaboration: Copenhagen, 2011.
22. Zar JH. Biostatistical Analysis. 2nd edn. Englewoods CliffsNew Jersey, USA: Prentice-Hall Inc, 1964.
23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
24. The Cochrane Collaboration. Review Manager (RevMan). The Cochrane Collaboration: Copenhagen, 2011.
25. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
26. Birlouez-Aragon I, Saavedra G, Tessier FJ, Galinier A, Ait-Ameur L, Lacoste F et al. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 2010; 91: 1220-1226.
27. Cai W, He JC, Zhu L, Peppa M, Lu C, Uribarri J et al. High levels of dietary advanced glycation end products transform low-density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation 2004; 110: 285-291.
28. Dittrich R, Dragonas C, Kannenkeril D, Hoffmann I, Mueller A, Beckmann MW et al. A diet rich in Maillard reaction products protects LDL against copper induced oxidation ex vivo, a human intervention trial. Food Res Int 2009; 42: 1315-1322.
29. Foerster A, Henle T. Glycation in food and metabolic transit of dietary AGEs (advanced glycation end-products): studies on the urinary excretion of pyrraline. Biochem Soc Trans 2003; 31: 1383-1385.
30. Harcourt BE, Sourris KC, Coughlan MT, Walker KZ, Dougherty SL, Andrikopoulos S et al. Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int 2011; 80: 190-198.
31. Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Götting C et al. Effects of low-and high-advanced glycation endproduct meals on macro-and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007; 85: 1236-1243.
32. Stirban A, Negrean M, Stratmann B, Götting C, Salomon J, Kleesiek K et al. Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method. Diabetes Care 2007; 30: 2514-2516.
33. Stirban A, Negrean M, Götting C, Uribarri J, Gawlowski T, Stratmann B et al. Dietary advanced glycation endproducts and oxidative stress: in vivo effects on endo-thelial function and adipokines. Ann N Y Acad Sci 2008; 1126: 276-279.
34. Stirban A, Negrean M, Götting C, Stratmann B, Gawlowski T, Mueller-Roesel M et al. Leptin decreases postprandially in people with type 2 diabetes, an effect reduced by the cooking method. Horm Metab Res 2008; 40: 896-900.
35. Schiekofer S, Franke S, Andrassy M, Chen J, Rudofsky G, Schneider JG et al. Postprandial mononuclear NF-kappaB activation is independent of the AGE-content of a single meal. Exp Clin Endocrinol Diabetes 2006; 114: 160-167.
36. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003; 14: 728-731.
37. Peppa M, Uribarri J, Cai W, Lu M, Vlassara H et al. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis 2004; 43: 690-695.
38. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 2011; 34: 1610-1616.
39. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99: 15596-15601.
40. Vlassara H, Cai W, Goodman S, Pyzik R, Yong A, Chen X et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 2009; 94: 4483-4491.
41. Gugliucci A, Kotani K, Taing J, Matsuoka Y, Sano Y, Yoshimura M et al. Short-term low calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab 2009; 54: 197-201.
42. Pashikanti S, de Alba DR, Boissonneault GA, Cervantes-Laurean D et al. Rutin metabolites: novel inhibitors of nonoxidative advanced glycation end products. Free Radic Biol Med 2010; 48: 656-663.
43. De La Maza MP, Leiva BA, Gattas V, Petermann M, Garrido F, Hirsch S et al. Fluorescent serum and urinary advanced glycoxidation end-products in non-diabetic subjects. Biol Res 2007; 40: 2003-2012.
44. Piroddi M, Palazzetti I, Quintaliani G, Pilolli F, Montaldi M, Valentina V et al. Circulating levels and dietary intake of the advanced glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study. J Ren Nutr 2011; 21: 329-339.
45. Semba RD, Ang A, Talegawkar S, Crasto C, Dalal M, Jardack P et al. Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation endproduct, in adults: the Energetics Study. Eur J Clin Nutr 2012; 66: 3-9.
46. Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets. Curr Drug Targets 2009; 10: 42-50.
47. Brown AA, Hu FB. Dietary modulation of endothelial function: implications for cardiovascular disease. Am J Clin Nutr 2001; 73: 673-686.
48. Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 2004; 80: 1029-1035.
49. Goldberg T, Cai W, Peppa M, Dardaine V, Baliga BS, Uribarri J et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 2004; 104: 1287-1291.
50. Uribarri J, Woodruff S, Goodman S, Cai W, Chen X, Pyzik R et al. Advanced gly-cation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 2010; 110: 911-916.
51. Tessier FJ. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol Biol 2010; 58: 214-219.
52. Ames JM. Determination of N epsilon-(carboxymethyl)lysine in foods and related systems. Ann N Y Acad Sci 2008; 1126: 20-24.
53. Assar SH, Moloney C, Lima M, Magee R, Ames JM. Determination of Nepsilon-(carboxymethyl)lysine in food systems by ultra performance liquid chromato-graphy-mass spectrometry. Amino Acids 2009; 36: 317-326.
54. Thornalley PJ. Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE)-an introduction. Mol Nutr Food Res 2007; 51: 1107-1110.
55. Heizmann CW. The mechanism by which dietary AGEs are a risk to human health is via their interaction with RAGE: arguing against the motion. Mol Nutr Food Res 2007; 51: 1116-1119.
56. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008; 205: 2409-2417.
57. Caballero AE. Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch Med Res 2005; 36: 241-249.
58. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011; 64: 401-406.
59. Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, Cunningham K et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 2011; 106(Suppl 3): S5-S78.
60. Rohrmann S, Zoller D, Hermann S, Linseisen J. Intake of heterocyclic aromatic amines from meat in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heidelberg cohort. Br J Nutr 2007; 98: 1112-1115.